Bevacizumab in glioblastoma--still much to learn.


Glioblastoma, which remains one of the most lethal tumors, is associated with a median survival of only approximately 15 months, despite aggressive combination therapy. Interest in therapeutic targeting of the f lorid angiogenesis characteristic of glioblastoma led to several phase 2 trials of bevacizumab, a humanized monoclonal antibody targeted against… (More)
DOI: 10.1056/NEJMe1313309